Omnicell (OMCL) investor relations material

Strategic direction and leadership changes

• Focus on simplifying complex medication management for large providers with enterprise solutions.

• Leadership retooled with new COO and CFO to drive growth, margin improvement, and predictable earnings.

• New CFO brings experience in both capital and recurring revenue models, supporting transition to more flexible financial structures.

• Sales force expanded to capture new opportunities as the replacement cycle accelerates.

• 2025 identified as a trough year, with cost resets positioning for growth and margin expansion in 2026.

Product innovation and technology deployment

• Announced significant enterprise-focused product updates, emphasizing plug-and-play deployment and cloud-based management.

• XT Amplify and XT Extend upgrades offer customers more frequent refreshes and flexibility, moving away from the traditional 10-year cycle.

• OmniSphere, an internally developed, high-security, multi-tenant cloud platform, enables real-time updates and workflow enhancements across all customer segments.

• New pricing model for OmniSphere aligns fees with customer utilization, similar to the Epic model.

• Workflow and data analytics improvements empower health systems to optimize inventory and purchasing decisions.

Financial performance and guidance

• Revenue guidance raised twice in 2025, with 5%-6% top-line growth and adjusted EBITDA guidance at $143 million.

• Improved scheduling and implementation efficiency accelerated backlog conversion, contributing to a $40 million upside in product revenue.

• Tariff headwinds managed through supply chain adjustments, pricing optimization, and cost discipline, limiting 2026 tariff impact to below $6 million per quarter.

• Revenue beats in products segment flowed through to EBITDA due to cost rationalization and operational initiatives.

• Recurring revenue streams from technical services and specialty pharmacy expected to support 2026 growth.